Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 25, 2026, 8:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 25 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Seasonal Allergic Rhinitis (SAR) Clear all
Completed Phase 3 Interventional Results available

Efficacy and Safety of GSP 301 Nasal Spray in Children (Aged 6 to Under 12 Years) With Seasonal Allergic Rhinitis (SAR)

NCT03463031
View directory record Official record
Conditions
Seasonal Allergic Rhinitis (SAR)
Interventions
GSP 301 NS, GSP 301 Placebo NS
Drug
Lead sponsor
Glenmark Specialty S.A.
Industry
Eligibility
6 Years to 11 Years
Enrollment
446 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
32
States / cities
Mission Viejo, California • Ontario, California • Paramount, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2019 · Synced Jun 25, 2026, 8:05 PM EDT
Completed Phase 3 Interventional

Once-Daily Investigational Nasal Spray In Adults And Adolescents With Seasonal Allergic Rhinitis (SAR)

NCT00197262
View directory record Official record
Conditions
Rhinitis, Allergic, Seasonal
Interventions
GW685698X Aqueous Nasal Spray
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
18
States / cities
Chicago, Illinois • Indianapolis, Indiana • Lafayette, Indiana + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2017 · Synced Jun 25, 2026, 8:05 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Trial of Dymista Nasal Spray in Children Ages 4 to 11 With Seasonal Allergic Rhinitis (SAR)

NCT01915823
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
azelastine hydrochloride and fluticasone propionate, Dymista vehicle
Drug
Lead sponsor
Meda Pharmaceuticals
Industry
Eligibility
4 Years to 11 Years
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
31
States / cities
Birmingham, Alabama • Little Rock, Alaska • Atlanta, Georgia + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2015 · Synced Jun 25, 2026, 8:05 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of GSP 301 Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (SAR)

NCT02870205
View directory record Official record
Conditions
Seasonal Allergic Rhinitis (SAR)
Interventions
GSP 301 NS, GOM-NS, GMM-2 NS, GSP 301 placebo NS
Drug
Lead sponsor
Glenmark Specialty S.A.
Industry
Eligibility
12 Years and older
Enrollment
1,176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
43
States / cities
Mission Viejo, California • Orange, California • San Diego, California + 33 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Jun 25, 2026, 8:05 PM EDT
Completed Phase 2 Interventional

Dose-ranging Study to Assess the Efficacy and Safety of Ciclesonide HFA Nasal Aerosol in Adult and Adolescent Patients 12 Years and Older With Seasonal Allergic Rhinitis (SAR) (BY9010/M1-602)

NCT00807053
View directory record Official record
Conditions
Rhinitis, Allergic, Seasonal
Interventions
Ciclesonide HFA, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years and older
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
31
States / cities
Mission Viejo, California • Orange, California • San Diego, California + 28 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2016 · Synced Jun 25, 2026, 8:05 PM EDT
Completed Phase 3 Interventional Results available

A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Seasonal Allergic Rhinitis (SAR)

NCT01458275
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Ciclesonide nasal aerosol 37 mcg, ciclesonide nasal aerosol 74 mcg, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
6 Years to 11 Years
Enrollment
847 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
66
States / cities
Little Rock, Arkansas • Baldwin Park, California • Costa Mesa, California + 49 more
Source: ClinicalTrials.gov public record
Updated May 14, 2014 · Synced Jun 25, 2026, 8:05 PM EDT
Completed Phase 3 Interventional

Seasonal Allergic Rhinitis In Pediatric Subjects

NCT00107757
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial
Interventions
GW685698X
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
2 Years to 12 Years
Enrollment
576 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
65
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Costa Mesa, California + 58 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2016 · Synced Jun 25, 2026, 8:05 PM EDT
Completed Phase 3 Interventional Results available

Clinical Trial to Assess the Efficacy and Safety of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol for the Treatment of Seasonal Allergic Rhinitis (SAR) to Mountain Cedar in Subjects 12 Years and Older

NCT01010971
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Ciclesonide HFA 160 μg, Ciclesonide HFA 80 μg, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
12 Years and older
Enrollment
671 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
7
States / cities
Austin, Texas • New Braunfels, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 12, 2012 · Synced Jun 25, 2026, 8:05 PM EDT
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy Study of rEV131 in Allergic Rhinitis

NCT00247520
View directory record Official record
Conditions
Hay Fever
Interventions
topical nasal rEV131
Drug
Lead sponsor
Evolutec Group
Industry
Eligibility
18 Years to 80 Years
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 1, 2005 · Synced Jun 25, 2026, 8:05 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Ciclesonide in Pediatric Patients (6 to 11 Years of Age) With Seasonal Allergic Rhinitis (BY9010/M1-417)

NCT00305487
View directory record Official record
Conditions
Hay Fever, Seasonal Allergic Rhinitis
Interventions
Ciclesonide nasal spray
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
6 Years to 11 Years
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
71
States / cities
Birmingham, Alabama • Hot Springs, Arkansas • Costa Mesa, California + 65 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2016 · Synced Jun 25, 2026, 8:05 PM EDT
Not listed Phase 2 Interventional

StahistRx Phase 2, Five-arm, Parallel Group, Active vs Active, Double-blind Study

NCT02082054
View directory record Official record
Conditions
Rhinitis, Seasonal, Allergic
Interventions
PSE 120 mg, CM 8 mg, Atr 0.36 mg, PSE 120 mg, CM 8 mg, Atr 0.24 mg, PSE 120 mg, CM 8 mg, Atr 0.12 mg, PSE 120 mg, CM 8 mg, Atropine 0.24 mg
Drug
Lead sponsor
Magna Pharmaceuticals, Inc.
Industry
Eligibility
12 Years to 60 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
4
States / cities
Stockbridge, Georgia • Louisville, Kentucky • Charleston, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated May 29, 2014 · Synced Jun 25, 2026, 8:05 PM EDT
Completed Phase 4 Interventional Results available

A Comparator Study of Fluticasone Propionate Nasal Spray Verses (vs) Cetirizine in the Treatment of Seasonal Allergic Rhinitis

NCT01916226
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial and Seasonal
Interventions
FPNS, FPNS Placebo, Cetirizine, Cetirizine Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
682 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
31
States / cities
Little Rock, Arkansas • Denver, Colorado • Aventura, Florida + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2018 · Synced Jun 25, 2026, 8:05 PM EDT
Completed Phase 3 Interventional Results available

Clinical Trial to Assess the Efficacy and Safety of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol for the Treatment of Seasonal Allergic Rhinitis

NCT00790023
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
80 mcg Ciclesonide, 160 mcg Ciclesonide, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
12 Years and older
Enrollment
707 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
4
States / cities
Austin, Texas • Kerrville, Texas • New Braunfels, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2016 · Synced Jun 25, 2026, 8:05 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Seasonal Allergic Rhinitis (SAR)

NCT02631551
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
GSP 301 NS, Olopatadine HCl NS, Mometasone furoate NS, GSP 301 Placebo NS
Drug
Lead sponsor
Glenmark Specialty S.A.
Industry
Eligibility
12 Years and older
Enrollment
1,180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
37
States / cities
Mission Viejo, California • San Diego, California • San Jose, California + 28 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2018 · Synced Jun 25, 2026, 8:05 PM EDT
Completed Phase 3 Interventional

A Safety and Bioequivalence of a Mometasone Nasal Spray, 50 mcg/Actuation Compared With Nasonex® Nasal Spray 50 mcg/Actuation in the Relief of the Symptoms of Seasonal Allergic Rhinitis (SAR)

NCT01673659
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Mometasone furoate, Nasonex Nasal Spray, Placebo nasal spray
Drug
Lead sponsor
Padagis LLC
Industry
Eligibility
12 Years to 65 Years
Enrollment
1,220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 21, 2021 · Synced Jun 25, 2026, 8:05 PM EDT
Completed Phase 2 Interventional

Efficacy, Safety and PK of Once or Twice Daily Bilastine (10 or 20 mg) Compared With Placebo in the Symptomatic Treatment of SAR

NCT00574379
View directory record Official record
Conditions
Seasonal Allergic Rhinitis, Hay Fever, Allergic Conjunctivitis, Hypersensitivity
Interventions
Bilastine, Placebo
Drug
Lead sponsor
Faes Farma, S.A.
Industry
Eligibility
12 Years and older
Enrollment
805 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
13
States / cities
Oklahoma City, Oklahoma • Austin, Texas • Kerrville, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2019 · Synced Jun 25, 2026, 8:05 PM EDT
Completed Phase 2 Interventional Results available

Bepotastine Besilate Nasal Sprays in the Treatment of Seasonal Allergic Rhinitis (SAR)

NCT01753739
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Bepotastine besilate, Placebo
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
12 Years and older
Enrollment
617 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Oct 4, 2020 · Synced Jun 25, 2026, 8:05 PM EDT
Completed Phase 2 Interventional

Study of ACT-129968 in Adult Patients With Seasonal Allergic Rhinitis

NCT01241214
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
ACT-129968, Cetirizine, Placebo
Drug
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Industry
Eligibility
18 Years to 70 Years
Enrollment
579 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
7
States / cities
Austin, Texas • Kerrville, Texas • New Braunfels, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated May 14, 2019 · Synced Jun 25, 2026, 8:05 PM EDT
Completed Phase 3 Interventional Results available

Study of an Investigational Nasal Aerosol or Placebo Nasal Aerosol in Children (Ages 6-11) With Seasonal Allergies

NCT01307319
View directory record Official record
Conditions
Seasonal Allergic Rhinitis, SAR
Interventions
BDP HFA, Placebo nasal aerosol
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
6 Years to 11 Years
Enrollment
715 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
45
States / cities
Oxford, Alabama • Bell, California • Costa Mesa, California + 40 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2015 · Synced Jun 25, 2026, 8:05 PM EDT
Completed Phase 3 Interventional Results available

Study in Adult and Adolescent Subjects With Seasonal Allergic Rhinitis (SAR)

NCT01024608
View directory record Official record
Conditions
Seasonal Allergic Rhinitis, Hay Fever
Interventions
Beclomethasone dipropionate, Placebo Nasal Aerosol
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
4
States / cities
Austin, Texas • New Braunfels, Texas • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2021 · Synced Jun 25, 2026, 8:05 PM EDT
Completed Phase 2 Interventional Results available

To Study GSP 301 in Patients With Seasonal Allergic Rhinitis

NCT02318303
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
GSP 301-1 NS (QD), GSP 301-2 NS (BID), GSP 301 Placebo NS, Olopatadine HCl-1 NS (QD), Olopatadine HCl-2 NS (BID), Mometasone Furoate-1 NS (QD), Mometasone Furoate-2 NS (BID)
Drug
Lead sponsor
Glenmark Pharmaceuticals Ltd. India
Industry
Eligibility
12 Years and older
Enrollment
1,111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
10
States / cities
Austin, Texas • Kerrville, Texas • New Braunfels, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Jun 25, 2026, 8:05 PM EDT
Completed Phase 3 Interventional

To Assess the Safety and Efficacy of Ciclesonide, Applied as a Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (BY9010/M1-401)

NCT00659841
View directory record Official record
Conditions
Rhinitis, Allergic, Seasonal, Hay Fever
Interventions
Ciclesonide, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years and older
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
6
States / cities
Austin, Texas • Kerrville, Texas • New Braunfels, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2016 · Synced Jun 25, 2026, 8:05 PM EDT
Completed Phase 3 Interventional

Trial of STAHIST in Seasonal Allergic Rhinitis

NCT01293201
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
STAHIST, Placebo
Drug
Lead sponsor
Magna Pharmaceuticals, Inc.
Industry
Eligibility
12 Years to 60 Years
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
8
States / cities
Stockbridge, Georgia • South Bend, Indiana • Louisville, Kentucky + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2011 · Synced Jun 25, 2026, 8:05 PM EDT
Completed Phase 2 Interventional Results available

Study to Assess the Efficacy and Safety of BDP HFA Nasal Aerosol in Patients 12 Years and Older With SAR

NCT00854360
View directory record Official record
Conditions
Seasonal Allergic Rhinitis, Hayfever
Interventions
Beclomethasone dipropionate HFA Nasal Aerosol, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
487 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
26
States / cities
Mission Viejo, California • San Diego, California • Colorado Springs, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated May 21, 2012 · Synced Jun 25, 2026, 8:05 PM EDT